• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Adding daratumumab increases progression free survival in multiple myeloma

byNeil D'SouzaandShaidah Deghan, MSc. MD
October 6, 2016
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The addition of daratumumab to standard therapy of lenalidomide and dexamethasone increased progression-free survival in relapsed or refractory multiple myeloma (MM).

2. Daratumumab was associated with a greater rate of infusion-related reactions and neutropenia compared to standard therapy alone.

Evidence Rating Level: 1 (Excellent)

Study Rundown: While the addition of proteasome inhibitors and immune modulators have improved outcomes for patients with MM, eventually relapse occurs. Prior phase1-2 trials with daratumumab (IgG monoclonal antibody targeting CD38) have shown improved response rates in patients with pre-treated relapsed or refractory MM using lenalidomide and dexamethasone. Given these results, this trial randomized daratumumab added to lenalidomide and dexamethasone, versus the latter two alone. The results showed a significant increase in disease-free survival, overall response and complete response or better in the daratumumab group compared to the standard group. However, there were more grade 3 or 4 adverse events in terms of neutropenia in the daratumumab group, as well as infusion related reactions compared to the control group. Nevertheless, these adverse events did not lead to higher death or treatment cessation rates. The major strengths of this trial were the large study numbers and randomization across multiple centers, and it built upon prior trials that demonstrated the added benefit of daratumumab. The main limitation was the lack of long-term data.

Click to read the study, published today in NEJM

Relevant Reading: Targeting CD38 with daratumumab monotherapy in multiple myeloma

In-Depth [randomized controlled trial]: This study randomized 569 patients with MM, who had prior treatment with one or more lines of therapy, to either lenalidomide and dexamethasone alone (control group) or combination with daratumumab (daratumumab). The primary endpoint was progression-free survival.

RELATED REPORTS

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide

Of the 569 patients enrolled in the trial, 286 were assigned to the daratumumab group and 283 to the control group. At the median follow-up time point of 13.5 months, there was a total of 169 events of disease progression or death, with 53 (18.5%) in the daratumumab group and 116 (41%) in the control group, for a HR of 0.37 (95%CI 0.27-0.52, p < 0.001). The progression-free survival at 12 months was 83.2% (95%CI 78.3-87.2) in the daratumumab group and 60.1% (95%CI 54-65.7) in the control group. The overall response rate that could be evaluated was 92% in the daratumumab group versus 76.4% in the control group (p < 0.001). In the daratumumab group, 51.9% of patients had grade 3 or 4 neutropenia, compared to 37% in the control group. Thrombocytopenia of grade 3 or 4 occurred in 12.7% of the treatment group and 13.5% of patients in the control group. The incidence of daratumumab infusion-related reaction of any grade was 47.7%, which included cough (8.5%), dyspnea (8.55%) and vomiting (5.7%).

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: multiple myeloma
Previous Post

Higher risk of type 2 diabetes associated with LDL-C-lowering genetic variants

Next Post

Overview of the 2014 measles outbreak in Ohio

RelatedReports

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma
StudyGraphics

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

February 3, 2022
#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide
StudyGraphics

#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide

January 27, 2022
#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma
StudyGraphics

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

December 18, 2021
Next Post
Significant percentage of pediatricians dismiss families who refuse vaccines

Overview of the 2014 measles outbreak in Ohio

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Quality in 30-day post-MI mortality linked to increased life expectancy

Ear infections decreasing in infants

Nonparental childcare attendance not linked to obesity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.